Get Critical Health Info

FORCE Blog

This blog will cover topics of interest that affect our community. Unless otherwise stated, the blog articles will be written by Sue Friedman, Executive Director of FORCE.

Get Involved > HBOC Community > FORCE Blog

| More

FORCE Blog

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 6,879 other subscribers

Archives

Posts Tagged ‘brca research’

May 18, 2017

Science and the Media: Help vs. Hype

by Piri Welcsh, PhD and Sue Friedman, DVM When making medical decisions, getting information right is more important than getting it fast. This is especially true for our community, when results of a genetic test or a breast biopsy can add a sense of urgency to medical decision-making. But finding factual data or input—help, not … + read more

May 14, 2017

The Lights of May

Special note: In honor of Mother’s Day 2017, and my son, Beau’s graduation which is next week, I’m recycling this post that I wrote in 2012. This post is as relevant as when I wrote it 5 years ago. I have yet to see a firefly in Tampa but tonight I will look extra hard. … + read more

May 11, 2017

Fueling Patient-Focused Health Care

by Melanie Nix I know a woman who has hereditary breast and ovarian cancer (HBOC) syndrome. She is a triple negative breast cancer survivor. She has a BRCA1 gene mutation and is the fifth generation in her family to have breast cancer. She lost her youngest aunt to ovarian cancer after multiple battles with both … + read more

March 28, 2017

SOLO3: A Clinical Trial Comparing the PARP Inhibitor, Olaparib to Standard Chemotherapy for Platinum-Sensitive Relapsed Ovarian Cancer

by Jordan Dietrich  SOLO3 SOLO3 is an exciting phase III ovarian cancer clinical trial that studies the effectiveness and safety of the PARP inhibitor Olaparib (Lynparza) compared to single-agent standard chemotherapy in women with platinum-sensitive relapsed ovarian cancer with germline BRCA1/2 mutations. The trial is designed to confirm the benefit of Olaparib in this subset of … + read more

March 1, 2017

Making Postmastectomy Decisions: The Right Input is Critical

Note: This is part 3 of a 3-part series related to our recent XRAYS review on Roni Caryn Rabin’s New York Times piece, “‘Going Flat’ After Breast Cancer.” In part 1 of the series, FORCE volunteer, Robin Karlin discusses her decisions after mastectomy, and her feelings post-reconstruction. In part 2, Sue Friedman talks about the affect of … + read more

January 31, 2017

MEDIOLA: A Clinical Trial Combining a PARP Inhibitor with an Immunotherapy Drug

By Ding Wang, MD and Catherine Jenovai Immune system and cancer Every day our bodies are exposed to various injuries that may damage our cells. The damaged cells with certain types of genetic defects are tagged as abnormal and removed by our immune system. If something goes wrong and the cells are not removed by … + read more

January 26, 2017

Flawed Research and Reporting on the “Angelina Effect” Could Threaten Access to HBOC Care

by Lisa Schlager, Lisa Rezende, PhD and Sue Friedman “Angeline Effect” Angelina Jolie’s May 2013 New York Times editorial “My Medical Choice,” which detailed her decision to have a double mastectomy because she carries a BRCA1 mutation brought unprecedented attention to hereditary cancer and BRCA genetic testing. This “Angelina Effect” created an avalanche of public … + read more

January 12, 2017

Update on Hormone Therapy for Previvors

by Alexandria Groves and Lisa Rezende, PhD National guidelines recommend that women with mutations in BRCA have risk-reducing removal of their ovaries and tubes, (also known as salpingo-oophorectomy or RRSO) either between the ages of 35-40 or after they are done having children. RRSO greatly reduces the risk of ovarian, fallopian tube, and peritoneal cancer, … + read more

December 31, 2016

Happy New Year HBOC Community! Happy 18th Birthday, FORCE!

Note: This post, which originally was published on 1/1/15 has been updated and reposted on 12/31/16. New Year’s is always a nostalgic time for me. Tonight at just a few seconds after the stroke of midnight, FORCE and the community we have built will turn 18! In 1999, I founded FORCE, not because I made … + read more

December 8, 2016

Tips for Sharing the Gift of Knowledge with Relatives

by Sue Friedman Members of our community who have already had genetic testing often ask for advice on how to speak about it to their relatives. Some common barriers to testing that we hear voiced by people are: concern over the cost of testing access to genetics experts family communication challenges With the holidays coming, … + read more

November 17, 2016

Results from the KNOW MORE Ovarian Cancer Survey: Your Comments

by Sue Friedman FORCE’s KNOW MORE campaign helps women diagnosed with ovarian, fallopian tube, or primary peritoneal cancers make informed decisions about genetic counseling and testing for inherited gene mutations. We launched a survey, which was completed by over 1,600 women with ovarian cancer. This blog continues our series on the survey results. We received over … + read more

November 14, 2016

Voices of FORCE: A BRCA Mutation is a Factor in Pancreatic Cancer

By Rona Greenberg Hereditary breast and ovarian cancer is part of my family history. My grandmother, Rebecca, for whom I am named, died from breast/ovarian cancer in1934; my mother was ten years old. My mother died from the same cancer in 1967; I was nineteen years old with three younger sisters. In 1997, I was … + read more

November 1, 2016

Learn About Hereditary Pancreatic Cancer

by Lisa Rezende, PhD November is Pancreatic Cancer Awareness Month. FORCE wants to raise awareness of the risk of pancreatic cancer in the hereditary cancer community. Pancreatic cancer is rare but BRCA carriers have a high risk, up to 5% compared to the 1.5% for the general population. Between BRCA carriers, the risk is higher … + read more

September 30, 2016

HBOC Week Special: Inherited Mutations in BRCA1/2 and Related Genes More Common Than Expected in Men with Advanced Prostate Cancer

Guest blog by Heather H. Cheng, MD, PhD Researchers have long been aware that prostate cancer carries a substantial familial risk. New data (Robinson, et al Cell 2015) from the Stand Up To Cancer-Prostate Cancer Foundation International Dream Team collaborative group examined the genetic sequence of 150 tumors from men with advanced, hormone-resistant, metastatic prostate … + read more

July 28, 2016

Metastatic Hereditary Breast Cancer Treatment Research: BROCADE 3 Study

By Heather Han, MD and Sue Friedman Metastatic Hereditary Breast Cancer Research There are major gaps in research, resources, and support for people with metastatic breast cancer – cancer that has spread beyond the breast and lymph nodes. A promising area of research is focusing on new treatments for hereditary metastatic breast cancer caused by … + read more

Connect with others.

Call our Helpline

Our helpline offers peer support for people concerned about hereditary cancer. All calls are confidential. Call any time.

Join a Local Group

FORCE has outreach groups throughout the United States and in Essex, United Kingdom that meet periodically to offer peer support, and share resources.

FORCE:Facing Our Risk of Cancer Empowered